ACTRN12622000974707
Recruiting
Phase 3
An open label pilot study investigating the in vivo detection of tetrahydrocannabinol (THC) in cannabidiol (CBD) dominant cannabinoid medications in cancer patients
Mater Misericordiae Limited0 sites30 target enrollmentJuly 11, 2022
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Mater Misericordiae Limited
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with histologically proven cancer known to the Cancer Care Service who:
- •\- Have had an ESAS TSDS greater than or equal to 10 for cancer or cancer\-treatment\-related symptoms, and at least one individual ESAS score greater than or equal to 3
- •\- Performance Status AKPS (Australia\-modified Karnofsky Scale score) of greater than or equal to 30
- •\- Aged 18 years, English\-speaking (or have an interpreter available)
- •\- Have a negative THC urine test at baseline
- •\- Have a negative pregnancy urine test at eligibility (only if of reproductive potential) and agree to avoid pregnancy during the study and 12 weeks following the last dose of the study drug. Males must agree to avoid fathering a child and to not donate sperm during the study and for at least 12 weeks following the last dose of the study drug
- •\- Are able to tolerate oral medications
- •\- Are willing to receive standard palliative care as necessary and delivered by their primary treating team
- •\- Physician assessed ability to comply with all trial requirements, agree to attend scheduled clinic appointments and adhere to dose titration schedules as directed
- •\- Agree to use no other cannabis\-based products for the duration of the trial
Exclusion Criteria
- •Patients with:
- •\- A history of hypersensitivity to any cannabinoid
- •\- Unstable untreated cardiovascular disease (hypertension, ischaemic heart disease, congestive cardiac failure)
- •\- Severe hepatic impairment (total bilirubin greater than or equal to 1\.5 times the upper limit of the institution’s normal range. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) greater than or equal to 3\.0 time the upper limit of the institution’s normal range; subjects with liver metastasis AST and ALT of greater than or equal to 5\.0 times the upper limit of normal
- •\- Severe renal impairment (eGFR greater than or equal to 20mL/min/1\.73m2\)
- •\- A history of psychiatric disorders (severe depression or anxiety, personality disorder, psychosis, schizophrenia)
- •\- Known substance use disorder (ASSIST \- Alcohol, Smoking and Substance Involvement Screening Test) examination scoring greater than or equal to 27 for any substance
- •\- History suggesting that drug diversion may be a risk for them or their family/carers
- •\- Females who are pregnant or lactating
- •\- Concurrent or participation in a trial of a new clinical entity within the last 28 days
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A Prospective Open Label pilot study investigating the impact of ThermaCare on flexibility, muscle relaxation & low back pain in two different populations.ow Back Pain > 3 WeeksACTRN12617000362392dorsaVi Ltd.40
Active, not recruiting
Phase 1
The effects of two brands of hydrocortisone injected intramuscularly into deltoid and thigh musclesAddison's DiseaseMedDRA version: 20.1Level: PTClassification code 10001130Term: Addison's diseaseSystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Body processes [G] - Metabolic Phenomena [G03]EUCTR2015-001090-40-GBThe London Clinic8
Active, not recruiting
Phase 1
anadelumab tested in patients suffering from hereditary angioedema with normal C1-Inhibitor.EUCTR2018-004136-30-DECharité - Universitätsmedizin Berlin Klinik für Dermatologie und Allergologie5
Not yet recruiting
Phase 2
To access the cost and effectiveness of Aripiprazole treatment in schizophrenia patients using gene based markersHealth Condition 1: F209- Schizophrenia, unspecifiedCTRI/2023/09/057176AJIITH XAVIER F
Completed
Not Applicable
Homeopathy in Treatment of Allergic RhinitisHealth Condition 1: null- Chronic Allergic RhinitisCTRI/2012/12/003193Mahesh Bhattacharyya Homeopathic Medical College and Hospital34